• Christoph Roderburg, Alexander Koch, Frank Tacke, Lukas Nieuwenhuijsen, Jan Bruensing, David Vargas Cardenas, Karina Kreggenwinkel, Mihael Vucur, Christiane Koppe, Philipp Jungebluth, Claudia Seikrit, Mark Luedde, Christian Trautwein, and Tom Luedde.
• Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
• J Crit Care. 2013 Oct 1; 28 (5): 882.e1-11.

IntroductionInflammatory and autoimmune diseases have been associated with the tumor necrosis factor superfamily member "A PRoliferation Inducing Ligand" (APRIL). However, up to now, APRIL has not been investigated in critical illness or sepsis. We therefore analyzed APRIL serum concentrations in a large cohort of well-characterized intensive care unit patients.MethodsSerum concentrations of APRIL were measured in 246 critically ill patients, of which 157 fulfilled sepsis criteria in comparison with 81 healthy controls. Clinical data were recorded and correlated with APRIL serum levels.ResultsWe detected strongly elevated serum levels of APRIL in critically ill patients compared with healthy controls. Levels of APRIL were further elevated in sepsis and significantly correlated with classical markers of inflammation, bacterial infection, or multiorgan failure. Consequently, high APRIL levels were associated with an unfavorable prognosis and predicted mortality with higher diagnostic accuracy than established prognostic scoring systems such as the Acute Physiology and Chronic Health Evaluation II score.ConclusionSerum levels of APRIL were significantly elevated in intensive care unit patients, with the highest concentrations in septic patients, and associated with unfavorable outcome. Besides being used as a single marker, APRIL may be implemented into established scoring systems to further improve their sensitivity and specificity in predicting patient's prognosis.Copyright © 2013 Elsevier Inc. All rights reserved.

71 keywords...

hide…